N/A
Completed N=80
Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
Source: ClinicalTrials.gov NCT02787057 ↗Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcomePrimary: Complete Cure Rate — 32; 31 Participants
Summary
Intra-peritoneal administration of antibiotics covering both gram-positive and gram-negative organisms was recommended as first-line regimen for the management of peritoneal dialysis related peritonitis. Oral administration of quinolones can also achieve effective serum concentrations, and is more convenient and economical. We conducted a pilot randomized controlled study to compare the effects on peritonitis cure and relapsing rates between oral moxifloxacin plus IP vancomycin and conventional IP vancomycin plus ceftazidime.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complete Cure Rate |
32; 31 | — |
| SECONDARY Primary Response Rate |
32; 27 | — |
| SECONDARY Primary Treatment Failure Rate |
8; 13 | — |
| SECONDARY Secondary Treatment Failure Rate |
5; 4 | — |
Eligibility Criteria
Inclusion Criteria
- incident or prevalent peritoneal dialysis patients
- diagnosis of acute peritonitis according to ISPD guideline
- age >18 years
Exclusion Criteria
- receiving antibiotic treatment for other reasons when peritonitis occurred
- contraindication to cephalosporin, vancomycin, or fluoroquinolones
- concomitant exit-site or tunnel infection
- requirement for immediate transfer to hemodialysis due to sepsis, gastrointestinal perforation or visceral inflammation, severe bowel obstruction, or ultrafiltration failure at the initiation of peritonitis
- inability to tolerate oral administration due to severe gastrointestinal complication or other reasons
- history of psychological illness or condition which interfered with ability to understand or comply with the requirements of the study
- pregnant or breast-feeding
Data sourced from ClinicalTrials.gov (NCT02787057). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.